Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$250 Mln
P/E Ratio
--
P/B Ratio
1.76
Industry P/E
--
Debt to Equity
0.74
ROE
-1.68 %
ROCE
-88.38 %
Div. Yield
0 %
Book Value
0.43
EPS
-0.59
CFO
$-767.40 Mln
EBITDA
$-799.88 Mln
Net Profit
$-804.57 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
| -9.44 | 17.23 | -28.09 | -57.67 | -29.27 | -20.61 | -21.39 |
|
BSE Sensex*
| 2.55 | 3.65 | 4.54 | 7.46 | 12.04 | 19.65 | 11.41 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Lexicon Pharmaceuticals (LXRX)
| -51.44 | -19.90 | -51.52 | 15.20 | -17.59 | -37.50 | -32.65 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.55 | 10,593.45 | 21.84 | 23.13 | |
| 306.35 | 8,570.17 | 22.78 | 66.44 | |
| 27.82 | 10,589.59 | -- | -28.77 | |
| 107.24 | 10,559.67 | 32.44 | 14.16 |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small... molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas. Address: 2445 Technology Forest Boulevard, The Woodlands, TX, United States, 77381 Read more
CEO & Director
Mr. Lonnel Coats
CEO & Director
Mr. Lonnel Coats
Headquarters
The Woodlands, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Lexicon Pharmaceuticals Inc (LXRX) stood at $ 298 Mln as on 31-Dec-24
The share price of Lexicon Pharmaceuticals Inc (LXRX) is $0.67 (NASDAQ) as of 29-Apr-2025 16:26 EDT. Lexicon Pharmaceuticals Inc (LXRX) has given a return of -29.27% in the last 3 years.
Lexicon Pharmaceuticals Inc (LXRX) has a market capitalisation of $ 250 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Lexicon Pharmaceuticals Inc (LXRX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Lexicon Pharmaceuticals Inc (LXRX) and enter the required number of quantities and click on buy to purchase the shares of Lexicon Pharmaceuticals Inc (LXRX).
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas. Address: 2445 Technology Forest Boulevard, The Woodlands, TX, United States, 77381
The CEO & director of Mr. Lonnel Coats. is Lexicon Pharmaceuticals Inc (LXRX), and CFO & Sr. VP is Mr. Lonnel Coats.
There is no promoter pledging in Lexicon Pharmaceuticals Inc (LXRX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Lexicon Pharmaceuticals Inc. (LXRX) | Ratios |
|---|---|
|
Return on equity(%)
|
-167.66
|
|
Operating margin(%)
|
-594.65
|
|
Net Margin(%)
|
-644.78
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Lexicon Pharmaceuticals Inc (LXRX) was $0 Mln.
$-0.02
(
